Physician

Hematology

Naoko N. Takebe, MD is an expert in the field of Hematology. Naoko Takebe is a published MD. She published 47 publications, including: 'Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reduct...'

Publications

---

• Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
• Perspectives on research activity in the USA on Cancer Precision Medicine.
• Biomarkers: Exceptional responders-discovering predictive biomarkers.
• Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity by Small Molecule GMX1778 Regulates Reactive Oxygen Species (ROS)-mediated Cytotoxicity in a p53-...
• Psychosocial factors are independent risk factors for the development of Type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tole...
• Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
• Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
• Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients.
• Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin''s lymphoma.
• Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.
• Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.
• Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene.
• Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated d...
• High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
• Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene.
• Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase...
• Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enr...
• Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors.
• Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reduct...
• Targeting the Hedgehog pathway in cancer.
• Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.
• KIT as a therapeutic target in metastatic melanoma.
• A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
• Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
• Principles and current strategies for targeting autophagy for cancer treatment.
• Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.
• Molecular conversations and the development of the hair follicle and basal cell carcinoma.
• Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
• Controversies in cancer stem cells: targeting embryonic signaling pathways.
• Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan.
• A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
• NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
• Preliminary findings on the use of pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell f...
• RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development.
• Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact.
• Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
• IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
• Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
• Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites.
• Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
• Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
• Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-flu...
• Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
• Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reducta...
• Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
• Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ...

Schools

---

• Hirosaki University School of Medicine

• Calif Pacific Med Center

• US Naval Hospital

• Keio University

• Meml Sloan Kettering Cancer Center

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

Education

---

• Memorial Sloan-Kettering Cancer Center
• California Pacific Medical Center - Pacific Campus

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Helen X. Chen, MD This Doctor is OpenDoctor Recommended.
	Dr. Farah Z. Zia, MD
	Dr. Nicholas J. Farrell, MD This Doctor is OpenDoctor Recommended.
	Dr. Paul A. Bannen, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert L. Justice III, MD
	Dr. Chaohong Fan, MD
	Dr. Richard J. Benjamin, MD
	Dr. Barnett S. Kramer, MD This Doctor is OpenDoctor Recommended.
	Dr. Neil E. Caporaso, MD
	Dr. Joseph C. Fratantoni, MD This Doctor is OpenDoctor Recommended.
	Dr. Angela Manns, MD
	Dr. Dongmei Wang, MD This Doctor is OpenDoctor Recommended.
	Dr. Chitra D. Rajagopal, MD This Doctor is OpenDoctor Recommended.
	Dr. Joseph M. Haggerty, MD This Doctor is OpenDoctor Recommended.
	Dr. John M. Wallmark, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog